Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets. I see near-term catalysts in the prostate BLA submission, Phase III AURORA NSCLC trial, and maturing glioma data, with execution risk now outweighing clinical risk.